Drug Trial Radar · NCT02826603
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Jul 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,114
Actual
Start
Jun 22, 2016
Primary completion
Jul 9, 2018
Study completion Jul 9, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
SecukinumabDrug
300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
UstekinumabDrug
Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12Time frame: Week 12
- Participants With IGA Mod 2011 0 or 1 at Week 12Time frame: Week 12
Locations
154 sites in 11 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Anniston, Alabama
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Glendale, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Scottsdale, Arizona
Novartis Investigative Site
Scottsdale, Arizona
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Fort Smith, Arkansas
Novartis Investigative Site
Hot Springs, Arkansas
Novartis Investigative Site
Rogers, Arkansas
Novartis Investigative Site
Bakersfield, California
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
California City, California
Novartis Investigative Site
Encinitas, California
Novartis Investigative Site
Fresno, California
Novartis Investigative Site
Fullerton, California
Novartis Investigative Site
Irvine, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Oceanside, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
Santa Monica, California
Novartis Investigative Site
Santa Rosa, California
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Trumbull, Connecticut
Novartis Investigative Site
Aventura, Florida
Novartis Investigative Site
Boca Raton, Florida
Novartis Investigative Site
Cape Coral, Florida
Novartis Investigative Site
Coral Gables, Florida
Novartis Investigative Site
Fort Myers, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Orange Park, Florida
Novartis Investigative Site
South Miami, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Tampa, Florida
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.